Mounjaro and eating disorders: what the clinical evidence actually tells us

What the SURMOUNT trials reported — and what they left out

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks and found average body-weight reductions of around 20–21% at the 15 mg dose. That headline figure is widely cited. Less discussed is who was excluded: the SURMOUNT programme systematically excluded participants with active or recently treated eating disorders, which means the robust efficacy and safety data we have does not cover this population directly. That gap matters.

What the trials do tell us is that tirzepatide's dual GIP and GLP-1 receptor agonism reliably suppresses appetite, slows gastric emptying, and shifts the experience of hunger and fullness in most people. For someone with a history of restriction (anorexia nervosa, for example) these effects can interact with existing thought patterns in ways that are difficult to predict from trial data alone. A prescriber needs to understand that history, not work around it.

The MHRA's NHS patient information for tirzepatide recommends telling your doctor about any mental health conditions, including eating disorders, before starting treatment. That is not bureaucratic box-ticking, it is the clinical rationale for the consultation existing at all.

Binge eating disorder: a more nuanced picture

The relationship between Mounjaro and binge eating disorder (BED) is distinct from the restrictive eating picture. BED involves recurrent episodes of eating large amounts in a short time, often with a sense of loss of control, and it carries significant overlap with obesity, meaning many people asking about Mounjaro also live with BED, whether formally diagnosed or not.

There is early clinical interest, and some emerging research, in GLP-1 and dual-agonist medicines as potential tools in BED management, partly because of their effects on reward-related eating behaviour and impulsivity around food. This research is at an early stage; it does not constitute a licensed indication, and it is not a reason to start tirzepatide independently of a clinical conversation. If binge eating is part of your history, the nuances of Mounjaro and binge eating disorder are covered in detail separately.

The practical implication is that BED does not automatically make tirzepatide unsuitable, but it makes proper clinical assessment more important, not less. A prescriber who skips the eating-behaviour history is not doing their job.

How appetite suppression changes eating, and why that needs active attention

One of the things our prescribers hear regularly is that patients were not prepared for quite how different their relationship with food would feel on tirzepatide. Appetite falls sharply, particularly in the first weeks and after each dose increase. For most people this is the intended effect; for someone with a history of restriction, it can feel like permission, a pharmacological reinforcement of an urge to eat very little.

This is not a reason to avoid Mounjaro categorically if a prescriber judges the balance of risk and benefit to be appropriate. It is a reason to have a plan. How eating changes on Mounjaro covers the practical side in detail, but the clinical principle is protein adequacy: people eating much less must still meet basic nutritional needs, and someone with a history of undereating needs to be particularly deliberate about this. The structured eating plan guidance our clinical team recommends is relevant here, not as a diet, but as a scaffold to keep nutrition on track when appetite signals have been altered. There is also a specific resource on what happens when you stop eating enough on Mounjaro, which addresses the muscle-loss and nutritional risks that can follow from under-fuelling.

For those wondering about specific food choices on treatment, what to eat on Mounjaro is a useful starting point, though individual guidance from a prescriber or dietitian always takes precedence over general advice.

The right conversation to have before you start

If you have a current or past eating disorder, two conversations matter before starting any weight-management medicine. The first is with whoever manages your mental health or eating disorder recovery, a GP, psychiatrist, or specialist team. The second is the clinical consultation with a prescriber, who needs the full picture, including that history, to make a responsible decision.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber (not automated software) the same day it is submitted. That means a real clinical person weighs your specific circumstances, including anything in your health history that warrants careful thought. If you would like to speak to a GP or eating disorder service first, Beat, the UK's eating disorder charity, can help direct you: Beat Eating Disorders.

The full Mounjaro overview covers licensing, eligibility and how the medicine works in detail. When you are ready to take the next step, start your free consultation and our prescribers will assess whether treatment is clinically appropriate for you.